Yasmin

Bayer plc

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before you are given Yervoy (ipilimumab) and during treatment with Yervoy (ipilimumab).

This risk minimisation material is a condition of the marketing authorisation.
If you would like a hard copy of the Yervoy (ipilimumab) risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; e-mail: medical.information@bms.com) with your specific request.